BACKGROUND: In previous clinical trials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney murine leukemia virus-based γ-retrovirus vector expressing interleukin-2 receptor γ-chain (γc) complementary DNA successfully restored immunity in most patients but resulted in vector-induced leukemia through enhancer-mediated mutagenesis in 25% of patients. We assessed the efficacy and safety of a self-inactivating retrovirus for the treatment of SCID-X1. METHODS: We enrolled nine boys with SCID-X1 in parallel trials in Europe and the United States to evaluate treatment with a self-inactivating (SIN) γ-retrovirus vector containing deletions in viral enhancer sequences expressing γc (SIN-γc). RESULTS: All patients received bone marrow-derived CD34+ cells transduced with the SIN-γc vector, without preparative conditioning. After 12.1 to 38.7 months of follow-up, eight of the nine children were still alive. One patient died from an overwhelming adenoviral infection before reconstitution with genetically modified T cells. Of the remaining eight patients, seven had recovery of peripheral-blood T cells that were functional and led to resolution of infections. The patients remained healthy thereafter. The kinetics of CD3+ T-cell recovery was not significantly different from that observed in previous trials. Assessment of insertion sites in peripheral blood from patients in the current trial as compared with those in previous trials revealed significantly less clustering of insertion sites within LMO2, MECOM, and other lymphoid proto-oncogenes in our patients. CONCLUSIONS: This modified γ-retrovirus vector was found to retain efficacy in the treatment of SCID-X1. The long-term effect of this therapy on leukemogenesis remains unknown. (Funded by the National Institutes of Health and others; ClinicalTrials.gov numbers, NCT01410019, NCT01175239, and NCT01129544.).
BACKGROUND: In previous clinical trials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney murine leukemia virus-based γ-retrovirus vector expressing interleukin-2 receptor γ-chain (γc) complementary DNA successfully restored immunity in most patients but resulted in vector-induced leukemia through enhancer-mediated mutagenesis in 25% of patients. We assessed the efficacy and safety of a self-inactivating retrovirus for the treatment of SCID-X1. METHODS: We enrolled nine boys with SCID-X1 in parallel trials in Europe and the United States to evaluate treatment with a self-inactivating (SIN) γ-retrovirus vector containing deletions in viral enhancer sequences expressing γc (SIN-γc). RESULTS: All patients received bone marrow-derived CD34+ cells transduced with the SIN-γc vector, without preparative conditioning. After 12.1 to 38.7 months of follow-up, eight of the nine children were still alive. One patient died from an overwhelming adenoviral infection before reconstitution with genetically modified T cells. Of the remaining eight patients, seven had recovery of peripheral-blood T cells that were functional and led to resolution of infections. The patients remained healthy thereafter. The kinetics of CD3+ T-cell recovery was not significantly different from that observed in previous trials. Assessment of insertion sites in peripheral blood from patients in the current trial as compared with those in previous trials revealed significantly less clustering of insertion sites within LMO2, MECOM, and other lymphoid proto-oncogenes in our patients. CONCLUSIONS: This modified γ-retrovirus vector was found to retain efficacy in the treatment of SCID-X1. The long-term effect of this therapy on leukemogenesis remains unknown. (Funded by the National Institutes of Health and others; ClinicalTrials.gov numbers, NCT01410019, NCT01175239, and NCT01129544.).
Authors: Lucinda Brown; Jinhua Xu-Bayford; Zoe Allwood; Mary Slatter; Andrew Cant; E Graham Davies; Paul Veys; Andrew R Gennery; H Bobby Gaspar Journal: Blood Date: 2011-01-27 Impact factor: 22.113
Authors: H Bobby Gaspar; Kathryn L Parsley; Steven Howe; Doug King; Kimberly C Gilmour; Joanna Sinclair; Gaby Brouns; Manfred Schmidt; Christof Von Kalle; Torben Barington; Marianne A Jakobsen; Hans O Christensen; Abdulaziz Al Ghonaium; Harry N White; John L Smith; Roland J Levinsky; Robin R Ali; Christine Kinnon; Adrian J Thrasher Journal: Lancet Date: 2004 Dec 18-31 Impact factor: 79.321
Authors: Gary P Wang; Charles C Berry; Nirav Malani; Philippe Leboulch; Alain Fischer; Salima Hacein-Bey-Abina; Marina Cavazzana-Calvo; Frederic D Bushman Journal: Blood Date: 2010-03-12 Impact factor: 22.113
Authors: M Noguchi; H Yi; H M Rosenblatt; A H Filipovich; S Adelstein; W S Modi; O W McBride; W J Leonard Journal: Cell Date: 1993-04-09 Impact factor: 41.582
Authors: Fabio Candotti; Kit L Shaw; Linda Muul; Denise Carbonaro; Robert Sokolic; Christopher Choi; Shepherd H Schurman; Elizabeth Garabedian; Chimene Kesserwan; G Jayashree Jagadeesh; Pei-Yu Fu; Eric Gschweng; Aaron Cooper; John F Tisdale; Kenneth I Weinberg; Gay M Crooks; Neena Kapoor; Ami Shah; Hisham Abdel-Azim; Xiao-Jin Yu; Monika Smogorzewska; Alan S Wayne; Howard M Rosenblatt; Carla M Davis; Celine Hanson; Radha G Rishi; Xiaoyan Wang; David Gjertson; Otto O Yang; Arumugam Balamurugan; Gerhard Bauer; Joanna A Ireland; Barbara C Engel; Gregory M Podsakoff; Michael S Hershfield; R Michael Blaese; Robertson Parkman; Donald B Kohn Journal: Blood Date: 2012-09-11 Impact factor: 22.113
Authors: H Bobby Gaspar; Samantha Cooray; Kimberly C Gilmour; Kathryn L Parsley; Stuart Adams; Steven J Howe; Abdulaziz Al Ghonaium; Jinhua Bayford; Lucinda Brown; E Graham Davies; Christine Kinnon; Adrian J Thrasher Journal: Sci Transl Med Date: 2011-08-24 Impact factor: 17.956
Authors: Troy Brady; Shoshannah L Roth; Nirav Malani; Gary P Wang; Charles C Berry; Philippe Leboulch; Salima Hacein-Bey-Abina; Marina Cavazzana-Calvo; Eirini P Papapetrou; Michel Sadelain; Harri Savilahti; Frederic D Bushman Journal: Nucleic Acids Res Date: 2011-03-16 Impact factor: 16.971
Authors: Olivier Humbert; Frieda Chan; Yogendra S Rajawat; Troy R Torgerson; Christopher R Burtner; Nicholas W Hubbard; Daniel Humphrys; Zachary K Norgaard; Patricia O'Donnell; Jennifer E Adair; Grant D Trobridge; Andrew M Scharenberg; Peter J Felsburg; David J Rawlings; Hans-Peter Kiem Journal: Blood Adv Date: 2018-05-08
Authors: Shubhranshu Debnath; Pekka Jaako; Kavitha Siva; Michael Rothe; Jun Chen; Maria Dahl; H Bobby Gaspar; Johan Flygare; Axel Schambach; Stefan Karlsson Journal: Mol Ther Date: 2017-04-20 Impact factor: 11.454